Immobilization and Application of Electrospun Nanofiber Scaffold-based Growth Factor in Bone Tissue Engineering.
Electrospun nanofibers have been extensively used in growth factor delivery and regenerative medicine due to many advantages including large surface area to volume ratio, high porosity, excellent loading capacity, ease of access and cost effectiveness. Their relatively large surface area is helpful for cell adhesion and growth factor loading, while storage and release of growth factor are essential to guide cellular behaviors and tissue formation and organization. In bone tissue engineering, growth factors are expected to transmit signals that stimulate cellular proliferation, migration, differentiation, metabolism, apoptosis and extracellular matrix (ECM) deposition. Bolus administration is not always an effective method for the delivery of growth factors because of their rapid diffusion from the target site and quick deactivation. Therefore, the integration of controlled release strategy within electrospun nanofibers can provide protection for growth factors against in vivo degradation, and can manipulate desired signal at an effective level with extended duration in local microenvironment to support tissue regeneration and repair which normally takes a much longer time. In this review, we provide an overview of growth factor delivery using biomimetic electrospun nanofiber scaffolds in bone tissue engineering. It begins with a brief introduction of different kinds of polymers that were used in electrospinning and their applications in bone tissue engineering. The review further focuses on the nanofiber-based growth factor delivery and summarizes the strategies of growth factors loading on the nanofiber scaffolds for bone tissue engineering applications. The perspectives on future challenges in this area are also pointed out.
Guobao
G
Chen
'111' Project Laboratory of Biomechanics and Tissue Repair, Bioengineering College, Chongqing University, 174 Shazheng Jie, Shapingba, Chongqing 400044, China. yglv@cqu.edu.cn.
Yonggang
Y
Lv
D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology / Q000627:therapeutic use; D001861:Bone Regeneration / Q000187:drug effects; D016503:Drug Delivery Systems / Q000379:methods; D005346:Fibroblast Growth Factors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D057139:Nanofibers / Q000008:administration & dosage / Q000627:therapeutic use*; D010982:Platelet-Derived Growth Factor / Q000008:administration & dosage / Q000627:therapeutic use; D023822:Tissue Engineering / Q000379:methods*; D054457:Tissue Scaffolds; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage / Q000627:therapeutic use
D019485:Bone Morphogenetic Proteins; D036341:Intercellular Signaling Peptides and Proteins; D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta; D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors